Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves Prometheus Test for Crohn's Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories today announced the New York State Department of Health has approved its proprietary Prometheus Crohn's Prognostic test for sale.

The test, which is performed in Prometheus' CLIA lab, combines six serologic markers and three genetic mutation markers and provides doctors with a personalized serologic profile for patients, the San Diego-based specialty pharmaceutical and diagnostics firm said. As a result, doctors can quantify patient risk for developing complications over time and determine appropriate treatments for patients.

In North America, between 400,000 and 600,000 people are affected by Crohn's disease, Prometheus said.